WindMIL Therapeutics Overview
- Year Founded
-
2015

- Status
-
Private
- Employees
-
11

- Latest Deal Type
-
2ndary - Private
- Investors
-
8
WindMIL Therapeutics General Information
Description
Developer of oncology cell therapies designed to translate novel insights in bone marrow immunology into life-saving systems for cancer patients. The company's therapies utilize re-activated T-cells that normally lie dormant and leverage bone marrow-derived lymphocytes to develop immunotherapies to treat cancer patients, enabling healthcare professionals to harness the unique immunologic properties of the bone marrow to lead the way in cancer cell therapies.
Contact Information
Website
www.windmiltx.comCorporate Office
- 1812 Ashland Avenue
- Suite 100
- Baltimore, MD 21205
- United States
Corporate Office
- 1812 Ashland Avenue
- Suite 100
- Baltimore, MD 21205
- United States
WindMIL Therapeutics Valuation & Funding
Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
---|---|---|---|---|---|---|
5. Secondary Transaction - Private | 01-Jan-2023 | Completed | Generating Revenue | |||
4. Later Stage VC | 26-Jan-2021 | Completed | Generating Revenue | |||
3. Early Stage VC (Series B) | 18-Jun-2018 | Completed | Generating Revenue | |||
2. Early Stage VC (Series A) | 07-Apr-2016 | $11M | $11M | Completed | Generating Revenue | |
1. Accelerator/Incubator | Completed | Startup |
WindMIL Therapeutics Cap Table
Stock | # of Shares Authorized |
Par Value | Dividend Rate ($) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
---|---|---|---|---|---|---|---|---|
Series B | ||||||||
Series A |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
WindMIL Therapeutics Comparisons
Industry
Financing
Details
WindMIL Therapeutics Competitors (83)
One of WindMIL Therapeutics’s 83 competitors is NexImmune, a Formerly VC-backed company based in Gaithersburg, MD.
Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
NexImmune | Formerly VC-backed | Gaithersburg, MD | ||||
Senti Bio | Formerly VC-backed | South San Francisco, CA | ||||
Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
Beacon Therapeutics | Venture Capital-Backed | Alachua, FL | ||||
DefiniGEN | Venture Capital-Backed | Cambridge, United Kingdom |
WindMIL Therapeutics Patents
WindMIL Therapeutics Recent Patent Activity
Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
---|---|---|---|---|---|
US-20230100744-A1 | Methods for enriching marrow infiltrating lymphocytes ("mils"), compositions containing enriched mils, and methods of using enriched mils | Pending | 28-Feb-2020 | ||
US-20220168350-A1 | Lung cancer specific marrow infiltrating lymphocytes and uses thereof | Inactive | 22-Mar-2019 | ||
US-20210154233-A1 | Marrow infiltrating lymphocytes (mils) expressing chimeric antigen receptors (car), method of manufacturing same, and method of using in therapy | Inactive | 30-Nov-2018 | ||
EP-3870191-A4 | Marrow infiltrating lymphocytes (mils) expressing chimeric antigen receptors (car), method of manufacturing same, and method of using in therapy | Pending | 30-Nov-2018 | ||
EP-3870191-A1 | Marrow infiltrating lymphocytes (mils) expressing chimeric antigen receptors (car), method of manufacturing same, and method of using in therapy | Pending | 30-Nov-2018 | C07K14/7051 |
WindMIL Therapeutics Signals
WindMIL Therapeutics Investors (8)
Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
---|---|---|---|---|
Catalio Capital Management | Venture Capital | Minority | ||
Forward Equity Partners | PE/Buyout | Majority | ||
FoxKiser | Corporation | Minority | ||
Kintegral Asset Management | Asset Manager | Minority | ||
Medivate Partners | PE/Buyout | Minority |
WindMIL Therapeutics FAQs
-
When was WindMIL Therapeutics founded?
WindMIL Therapeutics was founded in 2015.
-
Where is WindMIL Therapeutics headquartered?
WindMIL Therapeutics is headquartered in Baltimore, MD.
-
What is the size of WindMIL Therapeutics?
WindMIL Therapeutics has 11 total employees.
-
What industry is WindMIL Therapeutics in?
WindMIL Therapeutics’s primary industry is Biotechnology.
-
Is WindMIL Therapeutics a private or public company?
WindMIL Therapeutics is a Private company.
-
What is WindMIL Therapeutics’s current revenue?
The current revenue for WindMIL Therapeutics is
. -
How much funding has WindMIL Therapeutics raised over time?
WindMIL Therapeutics has raised $45.8M.
-
Who are WindMIL Therapeutics’s investors?
Catalio Capital Management, Forward Equity Partners, FoxKiser, Kintegral Asset Management, and Medivate Partners are 5 of 8 investors who have invested in WindMIL Therapeutics.
-
Who are WindMIL Therapeutics’s competitors?
NexImmune, Senti Bio, Kite Pharma, Beacon Therapeutics, and DefiniGEN are some of the 83 competitors of WindMIL Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »